Pressurised Intraperitoneal Aerosolised Chemotherapy-Results from the First Hundred Consecutive Procedures

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Apr 27

PMID 38672641

Authors

David Hoskovec

Zdenek Krska

Michal Vocka

Sona Argalacsova

Petr Dytrych

Affiliations

Soon will be listed here.

Abstract

PIPAC is a new and promising technique for the intraperitoneal administration of chemotherapy. It can be used in patients with various peritoneal cancer metastases. It is mainly a palliative treatment, but there is some neoadjuvant treatment potential. We have operated on 41 patients with various intra-abdominal cancers. PIPAC was performed every 6 weeks. The indication was extension of peritoneal carcinomatosis beyond the criteria for cytoreductive surgery and HIPEC. The effect was evaluated according to the peritoneal cancer index, the peritoneal regression grading score and the amount of ascites. Complications were classified according to the Clavien-Dindo system. We have performed 100 PIPAC procedures. There were two major complications, classified as Clavien Dindo III (2%). The number of procedures varied from 1 to 6. Five patients switched to cytoreductive surgery and HIPEC, and one was indicated for the watch and wait strategy due to total regression according to PRGS. Three patients are still continuing treatment. The others stopped treatment mainly because of progression of the disease and loss of metastases. We observed a reduction in ascites production soon after PIPAC application. PIPAC is a safe and well-tolerated treatment modality. It is mainly a palliative treatment that can improve the quality of life by reducing the production of ascites, but in about 10% of cases, it can reduce the extent of the disease and allow for further radical treatment.

References

Hoskovec D, Varga J, Konecna E, Antos F . Levels of CEA and Ca 19 - 9 in the sera and peritoneal cavity in patients with gastric and pancreatic cancers. Acta Cir Bras. 2012; 27(6):410-6. DOI: 10.1590/s0102-86502012000600009. View

Alyami M, Mercier F, Siebert M, Bonnot P, Laplace N, Villeneuve L . Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2019; 47(1):128-133. DOI: 10.1016/j.ejso.2019.06.028. View

Sullivan K, Raoof M . Evaluating End Points of the Efficacy of Intraperitoneal Chemotherapy Techniques Including PIPAC. Ann Surg Oncol. 2023; 30(5):2578-2581. DOI: 10.1245/s10434-023-13124-z. View

Rackauskas R, Bausys A, Luksta M, Jurgaitis J, Paskonis M, Strupas K . Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal malignancy: initial experience of the first program in the Baltic countries. World J Surg Oncol. 2021; 19(1):236. PMC: 8356452. DOI: 10.1186/s12957-021-02357-5. View

Sgarbura O, Villeneuve L, Alyami M, Bakrin N, Torrent J, Eveno C . Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?. Eur J Surg Oncol. 2020; 47(1):149-156. DOI: 10.1016/j.ejso.2020.08.020. View

Solass W, Kerb R, Murdter T, Giger-Pabst U, Strumberg D, Tempfer C . Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2013; 21(2):553-9. PMC: 3929768. DOI: 10.1245/s10434-013-3213-1. View

Alyami M, Hubner M, Grass F, Bakrin N, Villeneuve L, Laplace N . Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019; 20(7):e368-e377. DOI: 10.1016/S1470-2045(19)30318-3. View

Guchelaar N, Noordman B, Koolen S, Mostert B, Madsen E, Burger J . Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies. Drugs. 2023; 83(2):159-180. PMC: 9908703. DOI: 10.1007/s40265-022-01828-7. View

Mariano G, Pocard M, Eveno C . PIPAC: 8 key points for a good practice with video. J Visc Surg. 2019; 156(2):169-171. DOI: 10.1016/j.jviscsurg.2019.01.006. View

10.

Di Giorgio A, Macri A, Ferracci F, Robella M, Visaloco M, De Manzoni G . 10 Years of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): A Systematic Review and Meta-Analysis. Cancers (Basel). 2023; 15(4). PMC: 9954579. DOI: 10.3390/cancers15041125. View

11.

Roensholdt S, Detlefsen S, Mortensen M, Graversen M . Response Evaluation in Patients with Peritoneal Metastasis Treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). J Clin Med. 2023; 12(4). PMC: 9963217. DOI: 10.3390/jcm12041289. View

12.

Ndaw S, Hanser O, Kenepekian V, Vidal M, Melczer M, Remy A . Occupational exposure to platinum drugs during intraperitoneal chemotherapy. Biomonitoring and surface contamination. Toxicol Lett. 2018; 298:171-176. DOI: 10.1016/j.toxlet.2018.05.031. View

13.

Katdare N, Prabhu R, Mishra S, Mehta S, Bhatt A . Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Initial Experience from Indian Centers and a Review of Literature. Indian J Surg Oncol. 2019; 10(1):24-30. PMC: 6414563. DOI: 10.1007/s13193-018-0771-5. View

14.

Ellebaek S, Graversen M, Detlefsen S, Lundell L, Fristrup C, Pfeiffer P . Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study. Clin Exp Metastasis. 2020; 37(2):325-332. DOI: 10.1007/s10585-020-10023-5. View

15.

Verwaal V, van Tinteren H, van Ruth S, Zoetmulder F . Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004; 91(6):739-46. DOI: 10.1002/bjs.4516. View

16.

Nadiradze G, Horvath P, Sautkin Y, Archid R, Weinreich F, Konigsrainer A . Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Cancers (Basel). 2019; 12(1). PMC: 7016575. DOI: 10.3390/cancers12010034. View

17.

Jansen-Winkeln B, Eberth J, Moulla Y, Mehdorn M, Niebisch S, Schierle K . Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal surface malignancies (PSM): a prospective single-center registry study. J Cancer Res Clin Oncol. 2022; 149(3):1331-1341. PMC: 9984350. DOI: 10.1007/s00432-022-04517-w. View

18.

Balmer A, Clerc D, Toussaint L, Sgarbura O, Taibi A, Hubner M . Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases. Cancers (Basel). 2022; 14(10). PMC: 9139612. DOI: 10.3390/cancers14102557. View

19.

Hoskovec D, Varga J, Dytrych P, Konecna E, Matek J . Peritoneal lavage examination as a prognostic tool in cases of gastric cancer. Arch Med Sci. 2017; 13(3):612-616. PMC: 5420630. DOI: 10.5114/aoms.2016.64044. View

20.

Guel-Klein S, Alberto Vilchez M, Ceelen W, Rau B, Brandl A . Is PIPAC a Treatment Option in Upper and Lower Gastrointestinal Cancer with Peritoneal Metastasis?. Visc Med. 2022; 38(2):90-98. PMC: 9082136. DOI: 10.1159/000523901. View